Gastroprotective Drugs Market to Hit US$ 5.60 Billion by 2031 | Exclusive Report by Growth Plus Reports


Newark, New Castle, USA, May 29, 2023 (GLOBE NEWSWIRE) — The market analysis of the global gastroprotective drugs market was conducted by Growth Plus Reports in 2022 and was valued at US$ 4.53 billion. The market is expected to hit a revenue CAGR of 2.38% to reach US$ 5.60 billion by 2031.

Analysis of the global market for gastroprotective drugs indicates that the revenue share is likely to rise significantly. The management of gastrointestinal illnesses, such as inflammatory bowel diseases, peptic ulcers, and acid reflux, requires the use of gastroprotective medications.

Key Takeaways: 


  • According to estimates from the National Center for Biotechnology Information for 2019, gastritis accounts for around 1.8–2.1 million every year in the US.
  • According to the National Center for Biotechnology Information, 20–30% of individuals who take nonsteroidal anti-inflammatory medicines regularly get ulcers.
  • The prevalence of gastric disorders is increasing the market revenue growth rapidly.

Request a Sample Copy of the Research Report:

                   Gastroprotective Drugs Market Scope

Report Attribute Details
Market Size Value in 2022 US$ 4.53 billion
Revenue Forecast in 2031 US$ 5.60 billion
CAGR 2.38%
Base Year for Estimation 2022
Forecast Period 2023 to 2031
Historical Year 2021
Segments Covered Drug class, Application, and Region
Regional Scope North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa

Recent Development in the Gastroprotective Drugs Market: 

  • In January 2022, the generic version of Dexilant for the treatment of GERD, heartburn, and erosive esophagitis was made available in the US by TWI Pharmaceuticals.
  • In July 2019, The USFDA approved Zydus Cadila’s Misoprostol pills, which are used to treat stomach ulcers.

Competitive Landscape

A list of the companies operating in the global market for gastroprotective drugs includes: 

  • Sun Pharmaceutical Industries Ltd.
  • Salix Pharmaceuticals, Inc. 
  • Pfizer, Inc.
  • Gilead Sciences, Inc.
  • Cipla, Inc.

Market Drivers and Restraints: 

The global gastroprotective drugs market revenue is driven by gastrointestinal disorders such as reflux oesophagitis, gastritis, and duodenal and gastric ulcers. Furthermore, the high consumption of nonsteroidal anti-inflammatory drugs is causing gastrointestinal disorders and contributing to the market revenue share. 

Market Segmentation: 

  • Based on drug class, the global gastroprotective drugs market is segmented into antacids, histamine (h2) receptor antagonists, proton pump inhibitors, binding agents, and prostaglandin e analogs. 
  • Based on application, the global gastroprotective drugs market is segmented into gastric and duodenal ulceration, gastritis, reflux oesophagitis, ruminal acidosis, and others.         

Segmentation By Drug Class

Based on the drug class, the proton pump inhibitors segment dominates the global gastroprotective drugs market with a 30% revenue share. This large share of revenue is attributed to the increased prevalence of these illnesses, and the rising use of proton pump inhibitors as first-line treatments will fuel the development of this market over the coming years.

Request for Customization –

Regional Growth Dynamics

Based on the region, North America, with the largest revenue share, dominates the global gastroprotective drugs market. This sizable share of revenue share is attributed to the high prevalence of gastrointestinal disease. There are currently 60-70 million Americans who are experiencing gastrointestinal (GI) diseases driving regional revenue share. 

Report Coverage 

Growth Plus Reports carried out extensive market research on the gastroprotective drugs market globally. We examined the fundamental market characteristics, significant investment opportunities, regional growth patterns, ten-year revenue estimates, competing market players, and mergers and acquisitions.

Table of Content

    1. Market Ecosystem
    2. Timeline Under Consideration
      1. Historical Years – 2021
      2. Base Year – 2022
      3. Forecast Years – 2023 to 2031
    3. Currency Used in the Report
    1. Research Approach
    2. Data Collection Methodology
    3. Data Sources
      1. Secondary Sources 
      2. Primary Sources 
    4. Market Estimation Approach
      1. Bottom Up
      2. Top Down 
    5. Market Forecasting Model
    6. Limitations and Assumptions
    1. Current Market Trends (COVID-19 Perspective)
    2. Key Players & Competitive Positioning (2022) 
    3. Regulatory Landscape
    4. Reimbursement Scenario 
    1. Drivers
    2. Restraints/Challenges
    3. Opportunities
    1. Antacids
    2. Histamine (H2) Receptor Antagonists
    3. Proton Pump Inhibitors
    4. Binding Agents
    5.  Prostaglandin E Analogues
    1. Gastric and Duodenal Ulceration
    2. Gastritis
    3. Reflux Oesphagitis
    4. Rumenal Acidosis
    5.  Others


Buy this Premium Research Report:


  • Powered with Complimentary Analyst Hours and Expert Interviews with Each Report
  • Comprehensive quantitative and qualitative insights at segment and sub-segment level
  • Covid 19 impact trends and perspective
  • Granular insights at global/regional/country level
  • Deep-rooted insights on market dynamics (drivers, restraints, opportunities) and business environment
  • Blanket coverage on competitive landscape
  • Winning imperatives
  • Exhaustive coverage on ‘Strategic Developments’ registered by leading players of the market.


  • Distributor Landscape Assessment
  • Pricing Intelligence
  • Customer Base Assessment
  • Investment & Initiatives Analysis
  • ‘Business Profile’ of Key Players

Schedule a call with our analyst:

Visit our report store at –

Browse more latest healthcare reports:

Ultrasound Dissection Devices Market by Type (Hand-held Devices, Accessories), Application (Urology, General Surgery, Gynecology), End User (Hospitals, Ambulatory Surgical Centers) – Global Outlook & Forecast 2023-2031

Virtual Clinical Trials Market by Design (Observational, Interventional), Indication (CNS, Oncology), Phase (I, II) – Global Outlook & Forecast 2023-2031

Spectral Computed Tomography Market by Indication (Oncology, Cardiological Diseases), Product Type (Spiral CT, Electron Beam Tomography), Technology (Dual-layer Detector, Gemstone Spectral Imaging Detector), End User (Hospitals, Private clinics) – Global Outlook & Forecast 2023-2031

Sympathomimetic Drugs Market by Type (Direct, Indirect, Mized), Indications (Cardiovascular Diseases, Asthma & COPD), Distribution Channel (Hospitals Pharmacies, Retail Pharmacies) – Global Outlook & Forecast 2023-2031

Wireless Ultrasound Scanner Market by Product (Handheld Wireless Ultrasound Scanners, Portable Wireless Ultrasound Scanners), Application (Acute Care Units, Emergency Rooms), End User (Diagnostic Centers, Specialty Clinics) – Global Outlook & Forecast Period 2023-2031

Unleashing the Power of Innovation in Med Tech

About Us:

Growth Plus Reports is part of GRG Health, a global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association).

Growth Plus portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success.

We were awarded by the prestigious CEO Magazine as “Most Innovative Healthcare Market Research Company in 2020.

CONTACT: Manan Sethi Director, Market Insights Email: [email protected] 256 Chapman Road STE 105-4, Newark, New Castle - 19702, USA Phone no: +1 888 550 5009 Web:

Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. takes no editorial responsibility for the same.